Ironwood Pharmaceuticals, Inc. (IRWD) Stock Price Increases Today

February 15, 2018 - By Migdalia James

Investors sentiment decreased to 1.25 in 2017 Q3. Its down 0.06, from 1.31 in 2017Q2. It turned negative, as 24 investors sold Ironwood Pharmaceuticals, Inc. shares while 32 reduced holdings. 13 funds opened positions while 57 raised stakes. 154.60 million shares or 6.92% more from 144.60 million shares in 2017Q2 were reported.
Geode Management, a Massachusetts-based fund reported 1.21 million shares. 215,473 are owned by California State Teachers Retirement Sys. Vanguard Gp accumulated 11.02 million shares or 0.01% of the stock. Ecor1 Limited stated it has 5.46M shares or 11.47% of all its holdings. Teacher Retirement System Of Texas, a Texas-based fund reported 10,550 shares. Barclays Public Ltd Liability holds 5,100 shares. Amalgamated Natl Bank holds 17,141 shares. Bvf Incorporated Il owns 2.82 million shares for 5.65% of their portfolio. Ameritas Ptnrs Inc, Nebraska-based fund reported 11,821 shares. Dekabank Deutsche Girozentrale holds 0.01% or 58,900 shares. Brown Mngmt invested 1.19% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Credit Suisse Ag reported 0.02% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). The Ohio-based Strs Ohio has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). 103,131 are held by Manufacturers Life Comm The. Envestnet Asset Mgmt Inc has invested 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Since August 18, 2017, it had 0 insider purchases, and 3 sales for $983,540 activity. On Friday, August 18 the insider Consylman Gina sold $2,968. McHugh Julie sold $24,240 worth of stock or 1,500 shares. The insider OLANOFF LAWRENCE S sold 2,000 shares worth $32,300.

The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a huge mover today! The stock increased 7.56% or $1.095 during the last trading session, reaching $15.585. About 1.73M shares traded or 13.94% up from the average. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has risen 57.40% since February 15, 2017 and is uptrending. It has outperformed by 40.70% the S&P500.
The move comes after 5 months positive chart setup for the $2.33B company. It was reported on Feb, 15 by We have $16.21 PT which if reached, will make NASDAQ:IRWD worth $93.36M more.

Analysts await Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to report earnings on February, 20. They expect $-0.22 earnings per share, down 83.33 % or $0.10 from last year’s $-0.12 per share. After $-0.18 actual earnings per share reported by Ironwood Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 22.22 % negative EPS growth.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Among 15 analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD), 4 have Buy rating, 2 Sell and 9 Hold. Therefore 27% are positive. Ironwood Pharmaceuticals had 37 analyst reports since August 6, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, July 20 by Mizuho. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earned “Buy” rating by Mizuho on Friday, October 6. The firm has “Buy” rating by Mizuho given on Tuesday, June 6. The stock has “Hold” rating by Mizuho on Tuesday, January 9. On Thursday, April 28 the stock rating was maintained by Wedbush with “Neutral”. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has “Buy” rating given on Monday, October 10 by Mizuho. The firm has “Buy” rating by Cowen & Co given on Thursday, July 20. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has “Buy” rating given on Wednesday, August 2 by Mizuho. The stock has “Neutral” rating by Wedbush on Monday, October 24. The company was downgraded on Friday, January 5 by Bank of America.

More recent Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news were published by: which released: “Broderick Brian C Buys Ironwood Pharmaceuticals Inc, EOG Resources Inc …” on February 02, 2018. Also published the news titled: “Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Investor …” on February 01, 2018.‘s news article titled: “Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor …” with publication date: February 15, 2018 was also an interesting one.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $2.33 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.